Human Genetic Variation May Protect Against HCV-related Liver Disease Progression

2008-03-31 22:19:23

Human Genetic Variation May Protect Against HCV-related Liver Disease
Progression
Over years or decades, chronic hepatitis C virus (HCV) infection can lead to
advanced liver disease, including cirrhosis, hepatocellular carcinoma, and
end-stage liver failure. However, more than half of patients do not develop
severe liver disease, and the factors that influence outcomes are not well
understood.
In a report published in the December 2007 issue of Hepatology, researchers from
Los Alamos National Laboratory noted as background that previous studies have
shown statistical associations between human leukocyte antigen (HLA)
heterozygosity (presence of 2 different alleles, or genetic variants) and
favorable outcomes of infection with hepatitis B virus (HBV) or HIV -- a
phenomenon known as "heterozygote advantage."
In the present study, the authors investigated whether HLA zygosity is
associated with outcomes of HCV infection. They used data from the United States
Organ Procurement and Transplantation Network database of 52,435 liver
transplant recipients from 1995 through 2005. Of these, 30,397 were excluded for
lack of HLA data, re-transplantation, known HIV-HCV coinfection, or insufficient
information regarding HBV coinfection.
Results
. There was a significantly lower proportions of HLA-DRB1 heterozygosity among
HCV-infected compared with uninfected individuals.
. These differences were more pronounced with alleles represented as functional
supertypes than as low-resolution genotypes.
. No significant associations were observed between zygosity and HCV infection
other HLA locations.
Conclusion
"These findings constitute evidence for an advantage among carriers of different
supertype HLA-DRB1 alleles against HCV infection progression to end-stage liver
disease in a large-scale, long-term study population," the authors concluded.
They added that, "Considering HLA polymorphism in terms of supertype diversity
is recommended in strategies to design association studies for robust results
across populations and in trials to improve treatment options for patients with
chronic viral infection."
Finally, they wrote, "Access to de-identified clinical information relating
genetic variation to viral infection improves understanding of variation in
infection outcomes and might help to personalize medicine with treatment options
informed in part by human genetic variation."
01/04/08
Reference
P Hraber, C Kuiken, and K Yusim. Evidence for human leukocyte antigen
heterozygote advantage against hepatitis C virus infection. Hepatology 46(6):
1713-1721. December 2007.
http://www.hivandhepatitis.com:80/hep_c/news/2008/010407_b.html

2007-2008

2008-03-31 13:59:06

2007-2008
As we ushered in the New Year last night, the number on the calendar switched
from 7 to 8. This is not a mere changing of a digit but is an event which
creates unlimited possibilities and opportunities. Why is this phenomenon
especially strong on this year? Our sages teach us that the number 7 is the
definition of the natural Divine order of things. The world was created in 7
days. We have a 7 day week and so on.
The number eight - 8 - represents going beyond the natural boundaries. It
represents going beyond our natural - or more likely, going beyond our perceived
limitations. Turn "8" on its side and what do you get. The symbol for infinity.
So on a practical level, what does this mean to you? The greatest challenge we
all have is to get out of our own way. Quoting a line from the Declaration of
Independence: "We are all endowed by our Creator with Life, Liberty, and the
Pursuit of Happiness." But we are also endowed with tremendous talents and
abilities to help make the world a better place. We all have an abundance of
gifts that remain dormant in our lives. Now is the time to wake these concealed
talents up. Look at your life. What talents do you have that aren't being used?
Start using them. What gifts have you been given that you have hidden deep
inside of you. It's time that they be revealed. The number "8" shows us that we
have unlimited and endless possibilities in this world - and that we have to
break through our own self imposed ceilings to get there.
May 2008 bring you tremendous breakthroughs in your life.

Physicians Commonly Use Placebos to Placate Patients

2008-03-31 07:28:54

Physicians Commonly Use Placebos to Placate Patients
By Michael Smith, North American Correspondent, MedPage Today
Published: January 03, 2008
Reviewed by Zalman S. Agus, MD; Emeritus Professor
University of Pennsylvania School of Medicine.
CHICAGO, Jan. 3 -- A placebo as a panacea for patients is preferred, at least
some of the time, by nearly half the academic physicians who answered a survey
here.
And almost all the 231 clinicians who responded to the survey said they think
placebos can have a therapeutic effect, if only to mollify, placate, or pacify
patients, according to Rachel Sherman, a fourth-year medical student, and John
Hickner, M.D., both of the University of Chicago Pritzker School of Medicine.
Sixteen percent of respondents said they thought there was "often" a benefit to
placebos, although a common example was to prescribe antibiotics on demand for
nonbacterial diagnoses.
The findings suggest "a need for greater recognition of the use of
placebos and unproven therapies," the researchers said in the January issue of
the Journal of General Internal Medicine.
"It's largely unrecognized that physicians do prescribe placebos in their
practice," Sherman said.
The survey -- confined to physicians at the three major Chicago medical
schools -- can't be taken as representing what doctors do elsewhere in the U.S.,
she said, adding that a larger study is under way.
The researchers asked 466 doctors to answer a 16-question anonymous survey
on various aspects of placebo use and got responses from just under half.
Key findings:
a.. 45% reported they had used a placebo in clinical practice.
b.. Among those, the most common practice -- at 33% -- was prescribing
antibiotics for viral or other nonbacterial diagnoses.
c.. 20% had prescribed vitamins, 7% subtherapeutic doses of medication,
and 5% herbal supplements, while only 2% had actually given prepared placebo
tablets and only 1% had prescribed sugar or artificial sweetener pills.
d.. The most common reasons given were to calm the patient and as
supplemental treatment, at 18% each.
e.. 95% of respondents believed that placebos can have therapeutic
effects, although 21% said it was rare, 58% said it happened sometimes, and 16%
thought it occurred often.
f.. 68% agreed and 27% strongly agreed that "the placebo effect is
real."
g.. 40% said placebos could benefit patients physiologically for certain
health problems.
h.. 12% said that placebo use in routine medical care should be
categorically prohibited.
Interestingly, the researchers found, 80% disagreed with the statement: "I
think a placebo intervention can help distinguish symptoms that have a
psychogenic versus an organic origin."
That contrasts sharply with a 1979 study, in which a majority of doctors
said they used placebos to see if patient symptoms were "real."
Indeed, only 4% of the doctors who answered the survey said they had used
a placebo as a diagnostic tool.
The finding suggests "that a growing number of physicians believe in a
mind-body connection," the researchers said.
Of the doctors who said they used placebos, 34% told patients it was "a
substance that may help and will not hurt," but 19% described the placebo as
medication and 9% said it was "medicine with no specific effect."
Only 4% explicitly used the word "placebo," the researchers said.
Because the survey used a convenience sample, the researchers said, it may
not represent U.S. doctors in general. Also, while the survey was anonymous,
some doctors may have misreported their use of placebos. And finally, the data
are self-reported and retrospective, so that the possibility of recall bias
exists.
The study had no external financing. The researchers reported no
conflicts.
Primary source: Journal of General Internal Medicine
Source reference:
Sherman R, Hickner J, "Academic physicians use placebos in clinical
practice and believe in the mind-body connection" J Gen Intern Med 2008; DOI:
10.1007/s11606-007-0332-z.
http://www.medpagetoday.com/PrimaryCare/AlternativeMedicine/dh/7837

Sustained Virologic Response in Hepatitis C and Clinical Outcomes

2008-03-31 02:25:03

Sustained Virologic Response in Hepatitis C and Clinical Outcomes
A sustained virologic response was associated with a reduction in clinical
events, particularly liver failure.
Sustained virologic response (SVR) is the usual goal of hepatitis C treatment.
But is SVR associated with improved clinical outcomes? Researchers studied a
retrospective cohort of 479 treated patients at hepatology units; all had
advanced fibrosis or cirrhosis, and 30% (142 patients) achieved SVR (no
detectable hepatitis C virus RNA 24 weeks after the end of treatment).
During a median follow-up of 2 years, a clinical event (liver failure,
hepatocellular carcinoma, or death) was reported in only 3% of patients with SVR
but in 25% of those without SVR. No patients with SVR - but 12% of patients
without SVR - developed liver failure. These reductions in clinical events
remained significant in adjusted analyses. Substantial reductions in mortality
and hepatocellular carcinoma also occurred, but did not reach statistical
significance.
Comment: Even in hepatitis C patients with advanced fibrosis or cirrhosis,
sustained virologic response to antiviral therapy appears to be associated with
good clinical outcomes. In fact, the study may have underestimated the benefits
because the small number of events among those with SVR limited the power of the
study to detect them. But the challenge in the treatment of hepatitis C is
achieving SVR in the first place - a goal achieved by the minority of people
treated.
- Richard Saitz, MD, MPH, FACP, FASAM
Published in Journal Watch General Medicine January 2, 2008
Citation(s):
Veldt BJ et al. Sustained virologic response and clinical outcomes in patients
with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007 Nov 20;
147:677.

From death, four new lives

2008-03-30 15:43:45

Antoine Green's organ donation gave recipients a second chance.
By Bridget Murphy, The Times-Union
When the final medical test came back at 9 a.m. Wednesday, Antoine Green's
parents knew his brain was dead.
The Jacksonville couple already had seen the scan of the inside of his head, a
picture of five or six shards pocking it after a single bullet exploded into his
skull.
It bled too much life out of him.
So Linda Foster and Andrew Green began a 12-hour goodbye at their 18-year-old
son's bedside at Shands Jacksonville.
Then they turned his body over to the doctor, so surgeons could save what was
left.
So four other dying people could have a second chance at survival.
The parents said that at 2 p.m. Thursday, doctors harvested Antoine's heart,
liver, kidneys and pancreas. On Friday morning, the couple said it was their
son's gifts to four donor recipients that were keeping them going after his
slaying.
It was the city's first homicide in 2008, a year Antoine told his family he
would spend getting a good job and going back to school to finish getting his
high school diploma.
Instead, detectives are hunting for whoever shot him inside a Kenmore Street
house before rescuers got to his side about 12:30 a.m. Wednesday.
Since then, three of the victim's brothers, 16-year-old Nafis Green and twin
14-year-olds Michael and Marcus Foster, have been wearing his clothes, his
closest replacement.
And with some help from brother Michael, 8-year-old brother Damontre Green wrote
a verse he called All About Antoine Green that their parents plan to use as his
obituary.
"One day we was playing and goofing and the next day somebody shot and killed my
brother and his family was so worried at the hospital," it read in part.
His parents said they won't think of those last hours in the hospital when they
remember him.
They left before the machines that were keeping him alive stopped.
"I held him while he was still warm. ... I couldn't watch him take his last
breath. I remember him as still breathing, still feeling his heartbeat," his
mother said Friday.
"I'm still looking at it as he hadn't taken his last breath," his father said.
"It's going on in someone else."
bridget.murphy@... , (904) 359-4161
http://jacksonville.com/tu-online/stories/010508/met_231655780.shtml

The doctor will see you, anytime

2008-03-30 13:24:33

The doctor will see you, anytime
By DAVID GULLIVER
david.gulliver@...
At his former medical practice, Dr. Carlos Caballero was working 14 hours a day,
five days a week, and the occasional weekend.
He had about 4,000 patients and saw 25 to 30 of them a day, with his two
physician assistants seeing the same number.
"I was working harder then, and I was terrified," he said. "Your drive home is
sitting there thinking, 'Did I do everything I was supposed to do?'"
He is hardly slacking now. He works seven days a week, including 12-hour
weekdays and two to four hours on weekends.
But he seems considerably more relaxed, sitting on a sofa in an elegant side
room at his medical offices during a midday break from seeing patients.
Today he will see a half-dozen patients, spending an hour to 90 minutes with
each, and take phone calls from several others.
"It allows me to work better," Caballero said. "I think they're getting better
attention."
Welcome to the world commonly called concierge medicine, boutique medicine or,
as its practitioners now prefer, "direct practice."
In it, doctors essentially swap a high-volume, low-margin world for just the
opposite.
A study by the Government Accountability Office in 2005 is still the definitive
look at the style of practice.
The agency found concierge physicians take on far fewer patients, typically less
than 400, and each patient pays an annual fee, usually $1,500 but as much as
$15,000, in return for unlimited access to the doctor.
The result is guaranteed revenues of at least a half-million dollars a year, and
far more in wealthier areas where residents can afford higher prices.
The combination of less stress and more stable income proves alluring. While
only a handful of the country's doctors have gone to direct practice, their
numbers have grown rapidly.
There are about 500 such doctors across the country, reports the Society for
Innovative Medical Practice Design, which began as the American Society of
Concierge Physicians.
That represents a tripling from 2004, when the GAO found only 146 in its study.
The agency traced the trend's origin to MD2, a Seattle medical practice that
opened in 1996, founded by the former team doctor of the city's Supersonics
basketball team.
Most of the practices are clustered around affluent areas: GAO found the biggest
clusters in Seattle, Boston and West Palm Beach.
Caballero was Sarasota's first direct practice. He opened Private Physician
Services in October 2001. He has since added a partner.
Two years ago, two of Sarasota's most respected doctors -- and members of two of
its dominant practices -- opened their own boutique practice.
"We jumped at the opportunity, and haven't looked back since," said Dr. Louis
Cohen, partner with Dr. Brad Lerner in LernerCohen Healthcare.
Others probably will follow. Doctors of at least two Sarasota practices have
told patients or colleagues that they are considering charging patients an
annual retainer. Both said that they have not made a final decision.
But there are powerful draws for the direct-practice approach: Fewer hassles,
lower overhead, and certainly more money.
A doctor's view
At his old practice, Cohen would start his day at 6:30 a.m. with hospital
rounds, see patients in his office from 9 a.m. to 5:30 p.m., and at night
sometimes be the lone doctor on call for his group's 50,000 patients.
"Controlled bedlam," he said. "Was it the best way to deliver medicine? No, I
think absolutely not. Was it a necessity of the way medicine is practiced
nowadays? Yes."
Now he cares for 300 patients instead of 4,200. That day he had five scheduled
appointments, which allowed him to spend more time with each. The smaller
patient load also gives doctors more access to each person.
"We feel that allows us the ability to be there anytime the patients need us,
whether it be for a house call, for a nursing home visit, an office visit, to
give them the level of service that they want," Lerner said.
With the added attention comes special services. Caballero's Private Physicians
Services and LernerCohen both have dietitians on staff and draw blood in their
offices, services often handled at labs or hospitals.
The style benefits the doctors, too, in more ways than just reduced stress.
By having patients pay up front, they are essentially a cash business. They do
not have to haggle with insurance companies or government programs like Medicare
or Medicaid. That means they can save money -- at least $100,000 per year -- on
bookkeeping-type expenses.
They also likely make more money, by setting their own rates instead of
accepting declining reimbursements from Medicare and private insurers.
LernerCohen's prices range from $2,800 a year to $5,800 a year. Patients over
80, who they found required much more time, pay the highest rates. Caballero's
existing patients pay $2,500 to $4,000 per year, with those 65 and over paying
the higher rate.
Both practices have held prices constant for existing patients, in part by
charging a higher rate for newcomers; Caballero's is $7,500.
Doctors know the financial structure is both advantage and drawback.
"The only thing negative I can see about what we're doing is that everybody
doesn't have the opportunity to participate," Lerner said.
"This is a luxury item and it costs money like a luxury item. Not everybody can
afford the cost of this kind of service, and insurance companies won't pay for
this type of service."
LernerCohen and other concierge practices urge patients to maintain their
insurance or Medicare coverage. Medicare does not pay for concierge physicians'
fees, and by law the doctors cannot "double-dip" by billing Medicare. Concierge
physicians' fees cover only the primary doctor's services and pay neither for
specialists nor for hospitalization.
But multiply fees by patients, and a concierge practice can easily generate $1
million or more in revenue a year.
That has drawn scrutiny from the American Medical Association and the ire of
some doctors.
Another doctor's view
Dr. Randy J. Silverstine has worked 60- to 80-hour weeks in Sarasota since 1982,
earning incomes in the low six-figure range, he said.
His patients have included cabdrivers, professors, retired doctors -- and,
lately, many people who could no longer afford their doctors, he said.
So he views concierge medicine and its potential million-dollar revenues as
"unprofessional, unethical and a spectacular show of greed," he said.
"It's wanting to work less and make a phenomenal amount of money," he said.
"It's not a solution for health care in this country. It's health care for the
rich and famous."
Those questions have swirled around concierge medicine almost since its outset,
and practitioners are well aware.
In 2001, the American Medical Association voted to study the issue, and its
Council on Medical Service returned with the same answer: "A multitiered system
of care already exists in the United States."
The council saw no ethical problems with the concierge approach, pointing to
established AMA policies that say doctors have the right to set up their
practices as they want, and charge a fair fee established in a patient contract.
It also said there was "no evidence that special physician-patient contracts,
such as retainer agreements, adversely impact the quality of patients' care or
the access of any group of patients to care."
In fact, the council said the issue was overblown. "It would appear that the
amount of media coverage devoted to the subject has been disproportionate," the
report said.
But it did cite what it termed "risks" associated with concierge medicine: that
smaller patient loads might dull a doctor's skills, and that doctors switching
to a high-fee practice might leave some patients without care.
That was at the heart of Silverstine's lament.
"After developing real, meaningful, beautiful, caring relationships with many
patients and their families, how do you turn around and demand they now begin
paying 5 to 10 thousand dollars per head?" he asked.
"Just because something has a price doesn't mean it's right, doesn't mean that
it works or it's good for the profession or for the patients."
Some pay nothing
Concierge physicians are trying to counter that perception.
At Caballero's practice, 20 percent of the patients pay nothing for care, he
said.
Before a reporter's visit, he had given one such "scholarship" patient a
90-minute annual physical.
"We do it because it makes sense, but we also feel a need to work with the
community," he said.
As a medical student, people invested in him -- for example, letting a novice
draw blood and practice procedures.
"The community invested in me; I owe something back," he said.
LernerCohen does much the same. "A significant percentage of our practice are
completely scholarship, or at a reduced cost, because we felt an obligation,"
Lerner said. "We anticipated that would be a knock, and this was our way to
respond to it before it became an issue."
They also contend that concierge practices can produce better results because
they have more time to learn about their patients.
"The level of involvement and the level of care and the level of knowledge that
goes between patient and physician is infinitely higher," Cohen said.
Doctors with smaller patient loads can practice more preventive medicine,
catching small problems before they become expensive ones, Lerner said.
Not necessarily less work
But fewer patients does not mean less work, they contend.
"This is not an easy job," Lerner said. "We are each taking our own phone calls
24 hours a day, seven days a week. Every patient has access to" each doctor
"literally around the clock."
Not every doctor wants to be in that position, he said.
Nor can every physician attract hundreds of patients willing to pay thousands of
dollars a year that they did not have to pay before.
"You can't just hang up a shingle as an unknown quantity in a town like this and
expect to succeed in this type of practice," Lerner said.
He and Cohen have practiced medicine in Sarasota for more than two decades, both
of them founded prominent practices and both have been chief of medicine at
Sarasota Memorial Hospital..
Caballero practiced in Sarasota for only six years before starting his concierge
practice but carries an impressive resume, including Stanford Medical School and
residency at Harvard-affiliated Brigham and Women's Hospital.
About 100 of his 4,000 patients followed him to his concierge practice. Lerner
and Cohen started with about 300 patients, a similar percentage of their
original practices.
But patients who make the switch appear to be pleased. Caballero claimed 99
percent retention and a long waiting list. Lerner and Cohen declined to comment
on their retention but said they balance any attrition with new patients.
Not all such practices last. In 2003, Dr. Tony Trpkovski started a concierge
practice in Venice, reportedly spending $300,000 to outfit the offices. He later
closed it, worked for a time at a Venice-area clinic and is now practicing at
the Kauai Medical Clinic in Hawaii. He did not return calls seeking comment.
Still, the transition is becoming easier, in part because of a fast-growing
Florida company that claims concierge medicine produces better results.
The concierge playbook
Boca Raton-based MDVIP has essentially franchised concierge medicine for seven
years, making it easier for physicians to transition to the concept.
The privately held company now bills itself as the national leader in
"personalized and preventive health care."
"It is not enough to just put a toll booth at the practice's door," said Dr.
Edward Goldman, MDVIP's chief executive.
Now the company stresses its resources for disease prevention, such as its
affiliations with the Mayo Clinic, Cleveland Clinic, Memorial Sloan-Kettering
and other name institutions.
It also promotes its comprehensive "MDVIP physical," which concentrates on a
risk factor assessment as well as a battery of tests. The idea is to head off
illnesses before they start, as opposed to spotting them via tests like
mammograms and prostate-specific antigen checks.
"That is not prevention; that is early detection of disease," Goldman said.
"Let's look at your potential for illness. We don't want the pilot to get to
30,000 feet and find there's an engine knocking. Let's check it on the ground."
The prevention emphasis pays off, he said. MDVIP claims that its doctors'
patients were hospitalized 65 percent less frequently than Medicare
beneficiaries in 2005, and 85 percent less than commercial insurers' patients.
The statistics could not be independently confirmed.
MDVIP has grown to a network of 190 physicians and 65,000 patients, up from 154
physicians a year earlier -- not bad, considering the company rejects 80 percent
of doctors who apply, Goldman said.
The company's president, along with about 100 direct-practice physicians, turned
out recently for the Society of Innovative Medical Practice Design's annual
conference, outside of Washington, D.C.
Speakers including Newt Gingrich, former speaker of the House of
Representatives, led a roster of experts in preventive medicine, information
technology and health care finance.
Society President Chris Ewin said a more widespread acceptance of direct
practice medicine could break physicians' dependence on Medicare and private
insurance -- something he and his colleagues already enjoy.
"Some of us will never work for the government or the insurance industry again,"
he said.
_______
To read about concierge medicine from patients' perspectives, check out
Tuesday's Health + Fitness section.
http://www.heraldtribune.com/article/20080106/BUSINESS/801060870/1270/NEWS0101

What's Wrong with Blood Transfusions?

2008-03-30 04:00:28

Dr.Kattlove's Cancer Blog
What's Wrong with Blood Transfusions?
Who wants a blood transfusion? Mention blood transfusion to most people and
watch them scowl. Too dangerous they say. This attitude, which exists not only
among patients, but also among doctors, has led to the huge popularity of the
red cell-stimulating drug Epoetin and its recent long-acting cousin Aranesp.
But today, Amgen's (maker of Epoetin and Aranesp) announced the results of their
own study of these drugs in women with breast cancer. They weren't encouraging
for those patients (or Amgen's shareholders). The study found that women who
received the drug to prevent anemia saw their cancers return more quickly and
were more likely to die. This is bad news, especially because these drugs have
been used for many years in cancer patients without any proven benefit, except
to Amgen shareholders.
I practiced before the advent of these drugs and when a patient became anemic
and had symptoms (shortness of breath, extreme fatigue), I recommended
transfusion. We had nothing else to offer, and it was clearly worthwhile when
patient were feeling symptoms of their anemia. By the way, after transfusion,
the breathing would improve, but often the fatigue wouldn't if the patient was
receiving chemotherapy.
But what about the risks of transfusion - AIDS, hepatitis and who knows what?
Well our blood supply turns out to be super-safe.
What's the chance of getting HIV infection (cause of AIDS)? Answer: One in 2.3
million
How about getting hepatitis C? Answer: One in 1.8 million.
Hepatitis B? Answer: One in 350,000.
West Nile virus? Answer: 23 cases so far after many millions of transfusions.
Other transmitted infections are also rare. The biggest safety factor is making
sure the patient gets properly matched blood. But, there are so many checks and
double checks that a mistake here is very unlikely. So what's wrong with blood
transfusions in place of these potentially hazardous drugs? Nothing. Transfusion
may even be cheaper.
The truth is, a little anemia isn't harmful. The main thrust of the Epoetin
marketing is that people on chemotherapy feel tired and this is in part due to
their anemia caused by the chemotherapy drugs. Not true. It's the chemotherapy
that wipes people out.
So give up on the red cell stimulating drugs. Tolerate a little anemia - it goes
away when the chemotherapy is complete - and if the anemia is bad and you feel
bad, get a blood transfusion.
http://kattlovecancerblog.blogspot.com/2008/01/whats-wrong-with-blood-transfusio\
ns.html

Law & Order premiere mimics the life of Jack Kevorkian, aka "Dr. Death"

2008-03-29 23:26:04

Law & Order premiere mimics the life of Jack Kevorkian, aka "Dr. Death"
How similar the plot was to reality!
Assisted death is still a sensitive and timely topic, and even the hit TV show
Law & Order is discussing this controversial topic.
Because of the assisted dying theme in Whale Song, I have read many articles
about right-to-die activist and retired pathologist Jack Kevorkian, who was
paroled in June 2007, after spending 8 years in prison. He had been convicted of
second-degree murder [People v. Kevorkian, 248 Mich. App. 373, 639 N.W. 2d 291
(2001)]. So when I sat down last night to watch the season premiere of Law &
Order, I was surprised at how similar the plot was to reality.
In the premiere of Law & Order, Jeremy Sisto joins the cast as Cyrus Lupo, a
detective who comes home after 4 years abroad and finds that his brother has
committed suicide by lethal injection. Shortly after, a second man is found dead
in the same manner, after being diagnosed with Lou Gehrig'''s disease. Both men
had their deaths videotaped, to be aired by a well-known television reporter.
This is similar to the real-life case of Thomas Youk, whose assisted death aired
on November 22, 1998, on 60 Minutes.
In the Law & Order episode, there is graphic mention of how the suicide machine
is used and the side effects of the drugs. It is then discovered that Lupo's
brother's death was assisted by a young woman who turns out to be the daughter
of a recent parolee (ironically nicknamed "Dr. Death") who spent 10 years in
prison, and detectives believe that he had something to do with the men's
deaths.
In many of the articles I read about Jack Kevorkian, he was referred to as "Dr.
Death". Many anti-right-to-die activists proclaim that Kevorkian's chosen
method--lethal injection--is painful and slow, making it an inhumane way to die.
But others argue that lethal injection, if done correctly, is fast and virtually
painless. Law & Order mentions that death can be painful, yet we see two men
slip away rather peacefully.
The first scene with the Kevorkian-like character shows a man who still holds
onto his beliefs but cannot do anything with them. He professes to the
detectives that because of his parole stipulations, he cannot help anyone who
wants an assisted death, and that it's the fault of the legal system. This is
also very much like the words of Jack Kevorkian, who proclaims that he will work
now towards changes in the laws, rather than violate his parole terms and break
the law. "I can't talk in detail about the procedure or advocate a procedure,
especially with individuals," Kevorkian says in a recent interview with Mike
Wallace of 60 Minutes.
Assisted death has been in the news a lot this past year. Dignitas, the Swiss
right-to-die organization was ousted from their offices and forced to make other
accomodations for their clients who come to them in their final days. Sharon and
Ozzie Osbourne loudly voiced their own personal assisted-suicide pact, should
either of them lose their mental faculties. (Some may argue that has already
happened.)
While Whale Song does have a theme (one of many) of assisted dying, the novel
itself neither condones nor condemns this personal of all choices. It is not the
key focus of the novel, which is why I have readers as young as 7 reading it and
loving it. The messages in Whale Song deal more with surviving traumatic
experiences, such as bullying, racism, the death of a mother, the loss of a
father. The message is really about redemption and forgiveness. Life does go on,
even after tragedy. And the messages I have received from readers of all ages
have expressed how much they have loved the delicate handling of assisted dying
and that it has opened doors to discussion with friends, spouses and kids.
http://www.mynews.in:80/fullstory.aspx?storyid=1678
The following sites are listed for information purposes only and represent both
sides of the argument on assisted dying. My personal belief is that one cannot
truly make such a decision unless in this situation. If I had to watch someone I
loved dying a slow and painful death with no hope of recovery and no quality of
life, I admit, I would be tempted to consider assisted dying. However, I cannot
say for sure that I would follow through.
Here are a few sites that may help you understand this issue.
Right to die/assisted dying organizations:
a.. Dying with Dignity
b.. Compassion & Choices
c.. Dignity in Dying - UK
d.. Final Exit Network
Pro-life oranizations:
a.. National Right to Life
b.. Euthanasia.com
c.. Californians Against Assisted Suicide
d.. Nightingale Alliance
~Cheryl Kaye Tardif is a freelance journalist, book reviewer and bestselling
author of Whale Song, The River and Divine Intervention.
http://www.cherylktardif.com

Choi declared dead, organs donated to transplant patients

2008-03-29 17:39:22

Choi declared dead, organs donated to transplant patients
AP, SEOUL
Friday, Jan 04, 2008, Page 23
South Korean boxer Choi Yo-sam, who fell into a coma after winning his WBO
intercontinental flyweight title fight last week, was declared officially dead
early yesterday, a hospital spokesman said.
The declaration was made at 12:18am as doctors stopped the flow of blood to
Choi's heart and took him off life support, said Shin Dae-sung, a spokesman at
Asan Hospital in Seoul, which received approval from Choi's family.
His heart, liver, both kidneys and both corneas were removed for donation to six
patients awaiting transplants, Shin said.
A 58-year-old woman received Choi's liver in an operation yesterday at a
hospital in Jeonju, 243km south of Seoul, her son said.
"I am very grateful to Choi and his family for making the hard decision," said
Seol Dong-mok, the woman's son.
Choi's funeral will be held tomorrow, according to the Korea Boxing Commission.
On Wednesday, a hospital committee pronounced Choi brain dead after conducting a
series of tests. He had been in a coma since shortly after winning the fight
against Indonesian opponent Heri Amol in Seoul on Dec. 25.
The 33-year-old South Korean, a former world champion, was knocked down just
before the end of the 12th and final round of the bout but got back up and was
declared the winner on points before collapsing.
Choi was the WBC light flyweight world champion from Oct. 1999 to July 2002, and
fought for the WBA light flyweight world title in Sept. 2004.
The South Korean government said yesterday it would award a medal to Choi in
recognition of the organ donation and victory in his last fight.
Kim Jong-min, South Korea's culture minister, was to deliver the award -- given
to people who further the development of sports in the country -- to Choi's
family members.
http://www.taipeitimes.com/News/sport/archives/2008/01/04/2003395662

COUPLE ISSUE PLEA FOR ORGAN DONORS

2008-03-29 12:23:31

COUPLE ISSUE PLEA FOR ORGAN DONORS
A Highland couple who have been waiting almost two years for a liver transplant
for their young daughter yesterday appealed for more people to carry a donor
card.
Two-year-old Aimee Gallon, from Sutherland, was just five-and-a-half-weeks old
when she was diagnosed with a rare liver condition, which has left her with
jaundice.
Although she underwent a battery of tests and a serious operation before she was
six weeks old, doctors are unable to cure her condition without a liver
transplant.
While her parents, Nicola Hughan, 25, and gamekeeper Steven Gallon, 34, wait for
the call telling them a matching organ has been found, Aimee has to take up to
10 doses of medication every day.
The couple, who live on the Skibo Estate, have to wake up to eight times during
the night to feed their daughter milk with extra nutrients, in an effort to keep
her at a healthy weight.
Now Miss Hughan, who supervises night cleaning staff at Skibo, has given her
backing to a campaign for a system of "presumed consent" for organ dona-tion.
Under the scheme, about which Health Secretary Nicola Sturgeon has said she is
"increasingly sympathetic", people would have to actually opt out of the organ
donor scheme.
Miss Hughan said: "We didn't think about organ donation at all until we had
Aimee - it wasn't part of our lives.
"Too many people don't think about, or don't tell anyone their wishes.
"It's a difficult issue, and I know we're obviously very biased, but I do think
there has to be a lot more publicity of children and adults who are affected by
the lack of transplant organs."
Miss Hughan, who has trained as a nurse, was told her daughter had biliary
atresia after undergoing a series of tests, including a liver biopsy, in
Aberdeen, in December 2005.
Around 80 babies in the UK are diagnosed with the disease every year.
It is caused when the bile duct becomes blocked, leading to a build-up of bile
in the liver, effectively poisoning the organ.
An operation, taking part of Aimee's bowel to form a duct to drain the bile from
the liver, was partially successful.
Now she is reasonably healthy, she is still on the list for a transplant, but
she is not at the top.
If her condition deteriorates, her parents intend to undergo the tests needed to
give her part of one of their livers, but for now the couple are trying to
ensure Aimee leads as normal a life as possible, even enrolling her in a nursery
at Alness.
Miss Hughan said: "We were very shocked when she was diagnosed.
"We are worried every time she gets ill - she just has to get a temperature and
we panic.
"But we try to be quite relaxed because she's so well herself. After two years,
we have to be normal for Aimee so she can lead a normal life.
"It's not quite a laid-back approach through, we're still always waiting for the
phone call to come."
http://www.thisisnorthscotland.co.uk/displayNode.jsp?nodeId=149664&command=displ\
ayContent&sourceNode=149490&contentPK=19455812&folderPk=85696&pNodeId=149221

The January 2008 hepc.bull is now online (Canada)

2008-03-29 09:03:14

Hi All:The January 2008 hepc.bull is now online
Hi everyone:
The January issue of the hepc.bull is now online.
You can check it out at www.hepcbc.ca. Scroll down until you see a link for the
hepc.bull (main frame) or for the "newsletter" (in the contents frame).
The bulletin is in pdf format. If for some reason you have problems, contact me
and I will email you a copy. Some browsers are having a problem with our server.
Joan King

Hepatitis patient sues, blames dental implants

2008-03-29 05:25:48

Hepatitis patient sues, blames dental implants
January 4, 2008
FROM STNG WIRE REPORTS
A woman who underwent dental implant surgery at a Chicago office is suing the
makers of products used in the surgery, after she learned the products had been
recalled and she had contracted Hepatitis C.
After undergoing a dental implant procedure at the University of Chicago that
utilized bone allograft products, Donna A. Drew was told about the recall and
was advised to undergo medical testing, according to a suit filed in Cook County
Circuit Court Friday.
After undergoing the testing, Drew was diagnosed with Hepatitis C.
The seven-count suit names Tutogen Medical, Inc., Biomedical Tissue Services,
Ltd., Zimmer Dental, Inc. and Apptec, Inc. - medical companies that were
involved in the making of the products.
Drew accuses the companies of failing to include adequate and sufficient
instructions and warnings to patients that the product could be contaminated.
The companies also inadequately designed, manufactured and tested the product,
allowing for contamination, the suit said.
The suit seeks an amount in excess of the jurisdiction limits, as well as court
fees.
http://www.suntimes.com/news/metro/727180,hepatitis010408.article

Judge fires his assistant, draws criticism

2008-03-28 22:35:02

Judge fires his assistant, draws criticism
The woman, his aide for 17 years, has cancer and was on leave.
By Paul Pinkham, The Times-Union
Twelve days before Christmas, Circuit Judge Aaron Bowden fired his 17-year
judicial assistant, who had been on leave since August with cancer.
The Jacksonville judge said he feared her prolonged illness would leave him
without an assistant at a time when the state had implemented a hiring freeze.
But his decision left Christine Birch, 54, with no medical, life or disability
insurance and has created a firestorm at the courthouse.
Chief Circuit Judge Donald Moran responded by calling Bowden "a no-good son of a
bitch," prompting Bowden to respond with a blistering e-mail defending his
decision and calling Moran's criticism irresponsible, unprofessional and
unseemly.
Other judges' assistants were also appalled by Birch's firing. They raised money
to pay her rent this month.
"If it can happen to one of us, it can happen to any of us," said Donna Vail,
who responded to Bowden's e-mail with one of her own. "Chris Birch has been a
loyal employee to Judge Bowden ... who has been terminated for strictly health
issues and not for her service to her judge."
Birch declined comment Thursday. But she thanked Moran in a handwritten note
last week for putting her back on the courthouse payroll in a rotating judicial
assistant's position. Birch was paid about $3,275 a month in her old job, and
the state paid her health insurance premium. Her new rotating position pays $750
less a month and requires her to pay her own premiums.
"I want to thank you with all my heart for going to bat for me," she wrote.
Birch, who has battled cancer for five years, went on leave Aug. 20. On Dec. 12,
Duval County Court Administrator Britt Beasley notified the judges that the
Florida Supreme Court had implemented a 60-day hiring freeze effective Dec. 15
because of a budget shortfall.
"Does that mean when I lose Chris I cannot have a JA [judicial assistant] for
two months?" Bowden asked Beasley in an e-mail obtained Thursday.
"I regret that your interpretation is correct," Beasley replied. "The
alternative would be to terminate Chris on Dec. 14."
But Moran's judicial assistant, Mary Lou Martinson, said she had assigned one of
the rotating assistants to Bowden full-time at his request.
On Dec. 13, Bowden wrote a letter to Birch, firing her. He said he was unable to
reach her by phone.
"It is apparent to me that you are not able to return to work within a
reasonable period of time," he told her. "... Thank you for your conscientious
and loyal service. You will always have a special place in my heart."
Moran said he was attending a judicial conference and didn't learn of the
decision until Dec. 21, when Birch called him. Bowden said in his e-mail that
the chief judge called him "to tell me that he was going to tell everyone he
knows 'what a no good son of a bitch you are' after which he hung up the phone."
Moran didn't dispute Bowden's recollection but said he also wished him Merry
Christmas.
"It was very upsetting and disappointing to me to see that he would treat
another person that works in the system like that," Moran said Thursday. "It was
a very cruel thing to do right before the holidays."
Bowden declined comment Thursday beyond the contents of his Dec. 23 e-mail. In
it, he said Birch didn't return his calls while on leave and "maintained an
optimistic but unrealistic attitude toward her illness." He said he encouraged
her to seek involuntary medical disability retirement but she refused.
He said if she died while on the payroll, he would have been without an
assistant for two months, "not an ideal situation for a judge."
"I am chagrined but not surprised that Judge Moran has the effrontery to
criticize me ... on a matter not within his purview as chief judge," Bowden
wrote in the e-mail. "I have no legal or moral obligation to confer with him on
the hiring or discharge of my judicial assistant."
Vail said Birch was shocked when she received Bowden's letter but has not
indicated a desire to sue. It would be an uphill battle because she appears to
have exhausted the maximum amount of time off allowed under family leave laws,
said employment lawyers contacted by the Times-Union. They said she might have
rights under the Florida Civil Rights Act, but disability cases have become
difficult to win under that law.
"She has fought the battle of her life the past five years, for herself, for her
children and to come back for Judge Bowden," Vail said. "To lose everything that
she's worked for the past 15 years, especially her medical insurance - and not
for any wrongdoing - it's unbelievable."
paul.pinkham@... , (904) 359-4107
http://jacksonville.com/tu-online/stories/010408/met_231313469.shtml

INFORMATION ON "PARTICIPATING IN CLINICAL TRIALS" NOW AVAILABLE ON NIHSENIORHEALTH.GOV

2008-03-28 15:31:55

INFORMATION ON "PARTICIPATING IN CLINICAL TRIALS" NOW AVAILABLE ON
NIHSENIORHEALTH.GOV
U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH NIH News
National Library of Medicine (NLM) <http://www.nlm.nih.gov/
For Immediate Release: Friday, January 4, 2008
CONTACT: Kathy Cravedi, 301-496-6308, <e-mail: cravedik@...
INFORMATION ON "PARTICIPATING IN CLINICAL TRIALS" NOW AVAILABLE ON
NIHSENIORHEALTH.GOV
What is a clinical trial and how does it work? What are the benefits and the
risks? If you are an older adult, should you consider participating in a
clinical trial? These and many other questions are addressed in "Participating
in Clinical Trials", a new topic just added to NIHSeniorHealth
<www.nihseniorhealth.gov
Medicine (NLM) and the National Institute on Aging (NIA), both components of the
National Institutes of Health (NIH).
"The new clinical trials topic on NIHSeniorHealth will help older adults
understand this vital area of medical research," says Donald A.B. Lindberg,
M.D., NLM director. "Older adults who log on to <NIHSeniorHealth.gov
information to help them make informed decisions, including questions they
should ask and the answers they should look for if they are thinking of joining
a trial."
Developed by the National Library of Medicine, "Participating in Clinical
Trials" is the latest addition to NIHSeniorHealth's roster of 33 topics
targeting the health interests of older adults.
The new topic explains basic terms, the types and phases of trials, the informed
consent process and the benefits, risks, and built-in safeguards for trial
participants.
"Clinical trials are a critical part of medical research," says Richard J.
Hodes, M.D., NIA director. "The risk of many diseases and conditions increases
with age, and it is important that clinical trials include older participants,
who can help researchers find out if a drug, therapy, lifestyle change, device
or medical test is safe and effective in the older population."
One of the fastest growing age groups using the Internet, older Americans
increasingly turn to the Internet for health information. In fact, 68 percent of
"wired" seniors surf for health and medical information when they go online.
NIHSeniorHealth, which is based on the latest research on cognition and aging,
features short, easy-to-read segments of information that can be accessed in a
variety of formats, including large-print type sizes, open-captioned videos and
even an audio version. Additional topics coming soon to the site include
Parkinson's disease, nutrition, and high blood cholesterol. The site links to
MedlinePlus, NLM's premier, more detailed site for consumer health information.
Information about federally and privately supported clinical trials conducted in
the U.S. and around the world is available at <www.clinicaltrials.gov
The NLM, the world's largest library of the health sciences, creates and
sponsors Web-based health information resources for the public and
professionals.
The NIA leads the federal effort supporting and conducting research on aging and
the health and well being of older people. Both are components of the NIH in
Bethesda, Md.
The National Institutes of Health (NIH) - The Nation's Medical Research Agency -
is comprised of 27 Institutes and Centers and is a component of the U. S.
Department of Health and Human Services. It is the primary Federal agency for
conducting and supporting basic, clinical, and translational medical research,
and investigates the causes, treatments, and cures for both common and rare
diseases. For more information about NIH and its programs, visit <www.nih.gov
##
This NIH News Release is available online at:
<http://www.nih.gov/news/pr/dec2008/nlm-04.htm

Agent Linked to Survival of Children with Acute Liver Failure

2008-03-28 04:44:39

Agent Linked to Survival of Children with Acute Liver Failure
By John Gever, Staff Writer, MedPage Today
Published: January 04, 2008
Reviewed by Zalman S. Agus, MD; Emeritus Professor
University of Pennsylvania School of Medicine.
LONDON, Jan. 4 -- More children with acute liver failure not related to
acetaminophen poisoning survived after N-acetylcysteine therapy was made
routine, researchers here said.
Ten-year actuarial survival among 111 children with non-acetaminophen
acute liver failure treated with N-acetylcysteine was 75%, compared with 50% for
58 children getting other treatment (P=0.009), Anil Dhawan, M.D., of King's
College Hospital, and colleagues, reported in the January issue of Liver
Transplantation.
But in an accompanying commentary, a University of Cincinnati group
dismissed out of hand any conclusion that N-acetylcysteine therapy was the cause
of the improved actuarial survival.
The London results emerged from the King's College Hospital's experience
with children from 1989 through 2004. In addition to improved actuarial
survival, the group also found that N-acetylcysteine therapy was linked to
shorter hospital stays (19 days versus 25 days, P=0.05) and fewer deaths after
transplantation (16% versus 39%, P=0.02).
N-acetylcysteine is used routinely to treat acute liver failure resulting
from acetaminophen overdose. Some hospitals have also adopted it as standard
therapy for other cases of acute liver failure, which are rare but often fatal.
The drug is thought to benefit these patients by increasing hepatic tissue
oxygenation and reducing inflammation, promoting liver cell survival. At King's
College Hospital, it was given by continuous IV infusion at 100 mg/kg/day until
liver function normalized or the patients underwent a liver transplant.
However, systematic evidence that the drug is safe and effective in these
patients has been lacking. In the accompanying commentary, Mike A. Leonis, M.D.,
Ph.D., and William F. Balistreri, M.D., of the University of Cincinnati,
insisted the evidence remains lacking.
The King's College investigators compared outcomes in 59 children
hospitalized with non-acetaminophen-related acute liver failure from 1989
through 1994, when N-acetylcysteine was not used, with outcomes in 111 children
treated later when the hospital had made N-acetylcysteine therapy routine in
such cases.
But other aspects of care also changed during the study period, and the
two groups of children differed in some respects.
Dr. Dhawan and colleagues reported that jaundice and ascites were more
common in the earlier group children. Blood tests including normalized
prothrombin ratio, bilirubin, and white cell counts also suggested that the
earlier patients had suffered more liver damage by the time they reached the
hospital.
In addition, supportive care and inotropic medication were more common in
children treated later.
Dr. Dhawan and colleagues also compared outcomes among children treated
with N-acetylcysteine from 1995 through 1999 with those treated from 2000
through 2004.
No children treated in the most recent period died after a liver
transplant, whereas post-transplant mortality among those receiving
N-acetylcysteine earlier was 25% (P=0.0002). Significantly more of the later
patients survived with their native livers (58% versus 32%, P=0.01).
In consideration of these factors, Dr. Dhawan and colleagues reached the
modest conclusions that N-acetylcysteine appears to be safe in
non-acetaminophen-related acute liver failure, and it "may have a positive
effect on the outcome."
Drs. Leonis and Balistreri interpreted the findings more harshly, saying
they suggest the improvement in outcome was not due to N-acetylcysteine
treatment at all. The best they could say for the drug was that it appeared to
do no harm, and a role in the improved outcomes could not be ruled out.
Two randomized trials of N-acetylcysteine for acute liver failure
unrelated to acetaminophen toxicity are now underway, one in children and the
other in adults. Both groups of scientists agreed that these trials should
provide solid evidence on the drug's usefulness in this group of patients.
No research funding sources or conflicts of interest were disclosed.
Primary source: Liver Transplantation
Source reference:
Kortsalioudaki C, et al "Safety and efficacy of N-acetylcysteine in
children with non-acetaminophen-induced acute liver failure" Liver
Transplantation 2008; 14: 25-30.
Additional source: Liver Transplantation
Source reference:
Leonis M, Balistreri W, "Is there a NAC to treating acute liver failure in
children?" Liver Transplantation 2008; 14: 7-8.
http://www.medpagetoday.com/Gastroenterology/GeneralHepatology/tb/7855

Pot Slows Cancer in Test Tube

2008-03-28 02:57:05

Pot Slows Cancer in Test Tube
Marijuana Ingredients Slow Invasion by Cervical and Lung Cancer Cells
By Daniel J. DeNoon
WebMD Medical News
Reviewed by Louise Chang, MD
Dec. 26, 2007 -- THC and another marijuana-derived compound slow the spread of
cervical and lung cancers, test-tube studies suggest.
The new findings add to the fast-growing number of animal and cell-culture
studies showing different anticancer effects for cannabinoids, chemical
compounds derived from marijuana.
Cannabinoids, and sometimes marijuana itself, are currently used to lessen the
nausea and pain experienced by many cancer patients. The new findings -- yet to
be proven in human studies -- suggest that cannabinoids may have a direct
anticancer effect.
"Cannabinoids' ... potential therapeutic benefit in the treatment of highly
invasive cancers should be addressed in clinical trials," conclude Robert Ramer,
PhD, and Burkhard Hinz, PhD, of the University of Rostock, Germany.
Might cannabinoids keep dangerous tumors from spreading throughout the body?
Ramer and Hinz set up an experiment in which invasive cervical and lung cancer
cells had make their way through a tissue-like gel. Even at very low
concentrations, the marijuana compounds THC and methanandamide (MA)
significantly slowed the invading cancer cells.
Doses of THC that reduce pain in cancer patients yield blood concentrations much
higher than the concentrations needed to inhibit cancer invasion.
"Thus the effects of THC on cell invasion occurred at therapeutically relevant
concentrations," Ramer and Hinz note.
The researchers are quick to point out that much more study is needed to find
out whether these test-tube results apply to tumor growth in animals and in
humans.
Ramer and Hinz report the findings in the Jan. 2, 2008 issue of the Journal of
the National Cancer Institute.
http://www.webmd.com/cancer/news/20071226/pot-slows-cancer-in-test-tube?ecd=wnl_\
smk_010408

Son of former Longhorns baseball coach Gustafson dies of liver disease

2008-03-27 20:36:01

Son of former Longhorns baseball coach Gustafson dies of liver disease
HOUSTON -- Deron Gustafson, the son of former Texas baseball coach Cliff
Gustafson who was part of a financial controversy that led to his dad's
resignation, has died. He was 46.
Deron Gustafson's death Thursday at a Houston hospital was confirmed by the
Texas sports information department. He had suffered from liver disease in
recent years, his father told the Austin American-Statesman. He checked into an
Austin hospital Dec. 22 and was told his liver was working at 15 percent
capacity, his father said.
He was transferred to Houston's Memorial Hermann Hospital and had hoped to get a
liver transplant.
Deron Gustafson played for his dad at Texas from 1981-83 and was a volunteer
assistant for 13 years. The pair ran a baseball summer camp that in 1996 came
into question from UT officials because of finances.
An audit revealed a bank account with nearly $285,000 in revenue from summer
camps. NCAA rules prohibited volunteer coaches from getting paid for work at
summer camps.
Cliff Gustafson acknowledged paying his son through the account but said he
wasn't aware of any regulations preventing him from having the account. He said
any money paid to his son "were considered gifts, which I am allowed to give to
my children.''
After questions about the summer camps arose, Cliff Gustafson resigned. At the
time, he was the winningest coach in Division I baseball history with a record
of 1,466-377-2. He led the Longhorns to national championships in 1975 and '83.
Deron Gustafson played a season at Ranger Junior College before joining the
Longhorns. He was on the '83 championship team, hitting .306 in 18 games as a
backup second baseman.
He is survived by his wife, Julie; a daughter, Crosby; his father and his
mother, Janie; and his sisters, Jill Balderama and Jan Shepperd.
Services are scheduled for Monday in Austin.
http://sports.espn.go.com/ncaa/news/story?id=3181765

Hepatitis C drug's promise revitalizes Tampa firm

2008-03-27 07:57:33

Hepatitis C drug's promise revitalizes Tampa firm
St. Petersburg Times (FL) (KRT) - Jan. 04, 2008
Jan. 4--For the past 15 years, a little-known Tampa company has been barely
breaking even with a drug that treats gastrointestinal illnesses in children and
adults.
Now Romark Laboratories hopes to prove that the same medication is effective
against hepatitis C, the leading cause of liver transplants in the United
States.
If ongoing clinical trials are successful, it could transform Romark's drug,
Alinia, into a billion-dollar blockbuster. And it would be a breakthrough for
the more than 4-million Americans with hepatitis C, which can lead to cirrhosis,
liver failure and liver cancer.
With existing treatments effective only about half the time, specialists like
Dr. David Heiman in Tampa are eager to find new options for their hepatitis C
patients. "Anybody who shows me the next therapy is better than the current and
not significantly more dangerous, I'm on board," Heiman said.
Romark was cofounded in 1993 by veteran research scientist Dr. Jean-Francois
Rossignol and Tampa investment banker Marc Ayers. While working at France's
Pasteur Institute in the 1970s, Rossignol developed Alinia, known generically as
nitazoxanide, as an antiparasitic medication. But it wasn't until the early
1990s, after a career that included what is now GlaxoSmithKline and the World
Health Organization, that Rossignol revived his discovery for use against
parasitic infections in AIDS patients.
While Romark's medication worked, the demand declined in the late 1990s with the
introduction of new AIDS drugs. Moving forward with clinical trials, in 2002
Romark received FDA approval for Alinia to treat diarrhea caused by parasites in
children. Last year, the privately held company had about 50 employees and
$20-million in revenue.
Rossignol never considered testing Alinia against viruses until he got a call
from the FDA in late 2004. Researchers using the drug on AIDS patients found
their liver functions were improving. That raised the possibility that Alinia
could be effective against hepatitis C, a virus that scars the liver. Hepatitis
C is spread by contact with contaminated blood, such as needles shared by drug
users. Patients can carry the disease for 20 years before significant symptoms
develop.
Romark initiated a clinical trial of Alinia, in conjunction with the standard
hepatitis C treatment, on 96 patients in Egypt in late 2004. At the end of 2005,
Rossignol was en route to Cairo when he got a call from an excited colleague.
"Not only were patients' liver functions improved, but the decrease in the viral
load was dramatic," he said. "We were able to double the cure rate."
Romark presented the results of its Egyptian trial at a major conference of
liver specialists in Boston in early November. Though the data was preliminary
and the strain of hepatitis in Egypt differed from the one common in the United
States, the news caused a major upset in the race to cure hepatitis C.
Front-runner Vertex Pharmaceuticals of Cambridge, Mass., reported its
experimental compound, telaprevir, eliminated the hepatitis C virus in 61
percent of patients. Alinia, meanwhile, had been successful in 79 percent of its
Egyptian patients. Both companies tested their drugs in conjunction with the
current hepatitis C treatment of interferon and ribavirin. The standard
treatment has a success rate of just 40 to 50 percent.
None of the cures is cheap. The existing, two-drug combo, costs about $30,000
for 48 weeks. Romark's drug would cost an additional $30 a day; estimates of the
cost of Vertex's pill, which would be taken three times a day, are not
available.
Alinia's safety and apparent effectiveness have attracted the attention of
researchers at Stanford University School of Medicine. Rossignol was made an
affiliate faculty member at the California school and Dr. Jeffrey Glenn, a
Stanford gastroenterologist and Romark consultant, is studying how the drug
works.
Alinia is unique, Glenn said, because it targets the host cell, rather than the
hepatitis C virus. Other companies' compounds target the virus, attempting to
inhibit its ability to reproduce. But as viruses mutate, they can become
resistant, making the drugs less effective. The barrier to developing resistance
might be higher with a drug like Alinia that targets the host.
"Resistance is a huge problem in infectious diseases," Glenn said. "So we're not
only looking for a good drug, we're looking for how to deal with resistance."
Romark is testing Alinia, in conjunction with the standard treatment, in 120
U.S. hepatitis C patients, half of whom have failed prior treatment. It expects
to announce results of the trials by year end.
The company recently received $18-million from D.E. Shaw Group of New York City.
Ayers and Rossignol, who remain majority owners, expect that investment to carry
Romark through development of Alinia and related drug candidates. Ayers,
Romark's president and chief executive, said the company also intends to open a
research operation in Tampa this year, hiring 10 to 12 scientists.
After years of working virtually unnoticed by the giant pharmaceutical
companies, Romark suddenly has become a contender. The two men who have nurtured
the company this far scoffed at the notion that they would need help if they
find themselves with a hepatitis C blockbuster.
"It's not going to be easy, but we don't feel the need for a big pharma
partner," Rossignol said.
http://www.therapeuticsdaily.com/news/article.cfm?contentValue=1669466&contentTy\
pe=sentryarticle&channelID=26

Mingo Junction man needs dental work before liver transplant

2008-03-27 07:47:21

Mingo Junction man needs dental work before liver transplant
By DAVE GOSSETT, Staff writer
MINGO JUNCTION - Harold "Donnie" McMillen isn't looking for pity or sympathy
these days.
The 51-year-old Mingo Junction native is only looking for help in having six
teeth pulled. Without that dental work, McMillen cannot receive a liver
transplant that will save his life.
McMillen is currently at Trinity Medical Center West, going through yet another
procedure to have excess fluid drained from his stomach.
According to his wife Tanya McMillen, "the doctors say my husband's liver is now
weeping and the fluids build up in his stomach and then start building up in his
lower extremities. This is the fifth time he has had to have the procedure done
at the hospital and they drain about 15 liters of fluid each time."
Tanya is scheduled to take her husband back to the Cleveland Clinic on Friday
for another evaluation prior to being placed on the transplant list.
"But we are in a Catch 22 position. My husband's liver disease and his
medications have affected his teeth. So even though the Cleveland Clinic has
rated Donnie eligible for a liver transplant on the Model for End-Stage Liver
Disease system, they will not put him on the list until his last six teeth are
removed. They are afraid of performing a liver transplant and the procedure
getting an infection from his teeth," explained Tanya.
"If he doesn't get the transplant, his time is limited," she stated.
Tanya said her husband had his upper teeth removed by a Toronto dentist "a
couple months ago" after the dentist was assured by Medicaid officials that
Harold McMillen had dental coverage.
"We went back a week later to have the stitches removed and his lower teeth
pulled and were told the Medicaid people had changed their mind and said he had
no dental insurance beyond an annual cleaning and one filling a year. So the
dentist said he didn't want to put us into a deeper financial hole by pulling
the remaining six teeth," she said.
"I have been battling with Medicaid ever since then. My husband is receiving
Social Security disability payments and we started out under Medicare. They sent
us to the Cleveland Clinic for his medical treatments. But now we are under
Medicaid and they want us to go to Cincinnati. I have told the lady at the
Medicaid offices that it is a shorter trip to Cleveland and my husband is now
comfortable with the Cleveland doctors. But the Medicaid woman said it doesn't
matter. They want us to switch and start over in Cincinnati," she said.
"My cousin has called a number of dental offices in the area seeking help. But
the office managers refer us to a program that may help but it takes months for
approval. We don't have months to wait for approval," said Tanya.
"The dentist sent the paperwork required for assistance to our family physician,
Dr. William Johns, who filled out the papers and sent them to our insurance
company. But the application is now waiting for approval from a medical review
board which will take more time. And that is just not something we have at this
point," explained Tanya.
"We don't want any pity. But we are just asking if a dentist in the area is
willing to remove my husband's last six teeth so we can proceed with the liver
transplant evaluation at the Cleveland Clinic," Tanya noted.
She said she met her future husband when they were students at Mingo Junior High
School.
"We met in the seventh grade and were boyfriend and girlfriend. We dated through
high school and got married after that. We will be married for 30 years on Jan.
21," she added.
"We just had too much fun when we were young. That is what caused his liver
problems. My husband drank some alcohol and took too many Tylenol pills because
of the headaches," Tanya remarked.
"When my husband was first diagnosed on June 3, 2002, the doctors at the
Cleveland Clinic asked if he wanted to see his youngest child graduate from high
school. He told them 'yes' and he had several grandchildren he also wanted to
see graduate," related Tanya.
"So they told my husband he had to stop drinking and stop smoking. That was OK.
But they also told him he had to give up all his friends who drank and smoked
and make new friends. They didn't know my husband very well," Tanya said.
"He stopped drinking and smoking cold turkey. But he didn't give up his friends.
He still goes downtown to see his friends and watch the football games on
television. But now he drinks a soda instead of liquor," she said.
"And those same friends, and many more people in Mingo Junction, came together
at two different places downtown to hold benefits for us. People like Ed Fithen
at the Parkview and Lee Bell at the Shutzen Club helped us when we had to spend
four days for tests at the Cleveland Clinic. Their donations also helped us buy
a walker and wheelchair for my husband and helped us with home medical needs.
The people of Mingo Junction are absolutely wonderful. And we won't ever give up
our friends," Tanya promised.
"But if I could tell people one message from all of this I would say to be
careful about drinking alcohol and smoking. It can come back to hurt you," she
stated.
She noted she is spending, "close to $400 a month on medications for my
husband."
"He was recently diagnosed with Type 2 diabetes. That takes three different
medications a day. So a couple of my husband's doctors are giving us samples to
try and help us with the medications. And I have been to every pharmacy in the
area to check on the availability and the price of generic prescriptions," Tanya
said.
"My husband has always been a strong person. He worked for a Pittsburgh company
called Remacor where he traveled to steel mills all over the country and Canada
to test the de-sulphurization during the raw steel production process. Then his
company downsized, and he lost his job," she said.
"It really bothers him to need all this help and attention. He has always been
so strong. It just tugs at my heart," she noted.
Harold originally was rated an 11 on the MELD System five years ago.
"Two years ago, he was rated a 13. During our four-day stay at the Cleveland
Clinic at the end of November, my husband was rated at 18. The doctors feel he
will be above 20 when we go back on Friday. The MELD system ends at 40 points.
That number is fatal," said Tanya.
"It took two years for him to go up four points. Now he went up three points in
one month," she added with tears in her eyes.
"Right now we are battling the insurance company and dental offices as we ask
for help and most important of all, we are battling time. We really need help in
solving the dental issues so we can move forward and see my husband placed on
the liver transplant list," Tanya said.
"If he is placed on that transplant list, we then wait for a telephone call
telling us to go to the Cleveland Clinic. Once the call comes in, we have eight
hours to be at the clinic. They used to keep transplant patients for three
months after the operation. Now the patient is there from 10 to 14 days," Tanya
explained.
"But for my husband to get a liver transplant, I know another family has to
suffer because they have lost a loved one and agreed to donate the organs for
transplant," she commented.
As she sat in her living room the telephone rang with a message from a relative
at the hospital. Harold was becoming nauseated during his treatment.
"Find a nurse and ask if they can give him something for the nausea. I'll try to
be there by 3 o'clock," she replied.
"We are working shifts by having someone with Harold all the time he is in the
hospital," said Tanya.
"I am doing a lot of praying. God has always helped us to manage to find a way
through our problems. I really believe we will get through this. We just need a
little help," proclaimed Tanya. "That's all we need at this point. Just a little
help," she added.
(Gossett can be contacted at dgossett@....)
http://www.heraldstaronline.com/articles.asp?articleID=20766

Sister saves brother's life by donating liver lobe

2008-03-26 22:45:25

Sister saves brother's life by donating liver lobe
By JUDY SIEGEL-ITZKOVICH
A 30-year-old woman donated a lobe from her liver to her 10-year-old brother
this week - nine years after the sister donated bone marrow to him to treat his
congenital immune system disease. Their identities were not disclosed.
The liver transplantation, performed at Schneider Children's Medical Center of
Israel in Petah Tikva, was only the second reported case in the world - and the
first in Israel - in which a child received bone marrow and liver tissue from
the same donor.
Previously, there was only one Israeli case of a 17-year-old boy getting bone
marrow and a solid organ - a kidney - from the same donor. That procedure was
performed at the Rabin Medical Center-Beilinson Campus a few months ago.
As a result of the bone marrow/liver lobe combination, the 10-year-old boy will
not need to take potentially toxic anti-rejection drugs, which often carry
difficult side effects, for the rest of his life.
The sister, who is married and a mother of two, gave her bone marrow when her
brother was just a few months old. By doing so, she created a new immune system
- based on her own - for him that will not reject the liver lobe that she gave
him now.
The liver-lobe transplant was performed by Prof. Eitan Mor, head of Schneider's
transplant department; Dr. Ran Steinberg, deputy head of the surgical
department; Dr. Natan Bar-Natan, head of the pediatric transplant service; and
anesthesiologist Dr. Mila Kachko. Before the surgery, the boy was treated by Dr.
Yaron Avitzur, a gastroenterology and liver specialist.
The child is now recuperating in the pediatric ward headed by Prof. Ya'acov
Amir.
He needed the liver lobe as a result of rare and serious damage to his lungs
that reduced his blood oxygenation level to only 50 percent, instead of the 95%
in a healthy child.
Six months ago, his condition declined, and he needed a liver transplant. His
sister did not hesitate to give a lobe of her own; her liver will re-grow to its
original size over the coming year.
The liver lobe, said Schneider Medical Center doctors, will also improve his
lungs' function significantly, and he is expected to recover gradually from his
oxygenation problem in the coming months.
Nine Israeli children, and many more adults, are currently waiting for a liver
transplant. Due to the serious shortage of cadaver organs, Schneider Medical
Center has been using donations of a lobe from a live donor. Four such
liver-lobe transplants have been performed in the past year at the Petah Tikva
hospital, along with four taken from cadavers.
http://www.jpost.com/servlet/Satellite?cid=1198517278601&pagename=JPost%2FJPArti\
cle%2FShowFull

Out of the Gate: Vertex Pharma Falls

2008-03-26 15:40:53

Out of the Gate: Vertex Pharma Falls
Thursday January 3, 10:54 am ET
Vertex Pharma Shares Drop As Analyst Says Telaprevir Launch Could Be Delayed to
2012
NEW YORK (AP) -- Shares of Vertex Pharmaceuticals Inc., which traded at two-year
lows in recent days, slid in Thursday morning trading after a Wachovia analyst
downgraded the stock, saying new tests may delay the launch of hepatitis C drug
candidate telaprevir.
George Farmer said recent trials have been flawed, and as a result, Vertex will
have to conduct new trials to find the most effective doses of telaprevir. That
could push the drug's launch back two years to 2012, he said, hurting sales by
allowing competing drugs, like Schering-Plough Corp.'s boceprevir, to reach the
market first.
Farmer lowered his rating to "Underperform," or "Sell," from "Market Perform,"
or "Neutral." He said recent trial results indicate Vertex should run more
midstage trials, or perform a late-stage trial with patients receiving treatment
for up to 48 weeks.
The stock fell $1.81, or 7.8 percent, to $21.34 in morning trading, and reached
a low of $21.21.
Vertex reported midstage results from a telaprevir trial in November. Dropout
rates were high, and analysts were concerned by the drug's side effects, which
included fatigue, rash, headache and nausea.
"We believe the PROVE trial dropout rates support further Phase II dose
exploration before justifying Phase III advancement," Farmer said.

Insured, Wealthier Patients More Likely To Receive No-Cost Prescription Drug Samples From Physicians, According to Study

2008-03-26 14:28:38

Insured, Wealthier Patients More Likely To Receive No-Cost Prescription Drug
Samples From Physicians, According to Study
Wealthier, insured patients receive no-cost drug samples from physicians
more often than lower-income patients, according to a study published on
Wednesday in the American Journal of Public Health, USA Today reports. For the
study, Sarah Cutrona, a physician at Cambridge Health Alliance and professor at
Harvard Medical School, and colleagues used data from a 2003 Agency for
Healthcare Research and Quality survey of nearly 33,000 U.S. residents.
The study found that patients with the highest incomes were the most likely to
receive no-cost samples and that 28% of patients who received drug samples had
incomes less than 200% of the federal poverty level (Szabo, USA Today, 1/3).
Fewer than one-fifth of patients who received drug samples were uninsured at
some point during 2003, according to the study (Cooney, Boston Globe, 1/3).The
study does not indicate that physicians intentionally give drug samples to
patients with higher incomes (USA Today, 1/3).
The survey data show that where people received health care was a significant
factor in whether they received no-cost samples. Patients who saw their
physicians in offices were more likely to receive samples, and insured patients
with better access to care were more likely to see their doctor in an office
rather than in an emergency department or hospital clinic. Cutrona said, "That
finding suggests that the samples were a marketing tool and not a safety net
because the poor and uninsured patients were not finding their way to where the
samples were."
Cutrona added, "Doctors are trying to target samples to needy patients, but
their individual efforts failed to counteract societywide factors that determine
access to care."
According to the study, no-cost drugs samples with a retail value of $16.4
billion were given out in 2004, compared with $4.9 billion in 1996. Cutrona said
most of the samples were new, high-cost drugs. Cutrona added that no-cost
samples also raise patient safety concerns in part because they are not
dispensed by pharmacists who check for drug interactions (Boston Globe, 1/3).
Ken Johnson, senior vice president of the Pharmaceutical Research and
Manufacturers of America, said studies show that 75% of physicians frequently or
sometimes give out drug samples to help patients with out-of-pocket costs (USA
Today, 1/3). Johnson in a statement said, "Instead of second guessing motives,
Harvard researchers would better serve patients by examining health outcomes,"
adding, "Clearly, free samples often lead to improved quality of life for
millions of Americans, regardless of their income" (Boston Globe, 1/3).
An abstract of the study is available online.
NPR's "All Things Considered" on Wednesday reported on the study. The segment
includes comments from Richard Baron, a physician in Philadelphia; Cutrona; and
a spokesperson for PhRMA (Silberner, "All Things Considered," NPR, 1/2). Audio
of the segment is available online.
http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=49641

Shorter Hepatitis C treatment more successful and cost-effective

2008-03-26 09:09:16

Shorter Hepatitis C treatment more successful and cost-effective
Washington, Jan 3: A recent study has revealed that Hepatitis C (HCV), when
treated with peginterferon and ribavirin, for shorter durations, can yield
success rates similar to those from longer treatment lengths, with cost-savings
and lower risk of serious side effects.
Peginterferon are natural proteins produced by the cells of the immune system
and ribavirin is an anti-viral drug active against a number of DNA and RNA
virus.
The study led by Alessandra Mangia of Italy's Istituto di Ricovero e Cura a
Carattere Scientifico, Casa Sollievo Della Sofferenza, in San Giovanni Rotondo
conducted a randomised controlled trial of patients with HCV genotype 1.
The study included 696 patients, 237 of whom received standard HCV and 459 were
treated for 24, 48, or 72 weeks.
The findings revealed that about 49 percent of patients receiving variable
treatment based on detectable viral levels showed a persistent viral response,
as 45 percent of patients in the standard group.
The patients who showed a viral response at week 4 were treated by a 24-week
therapy and for those who did not show a response until week 12, 72 weeks of
treatment was required for an approximately similar cure rate.
"In conclusion, variable treatment duration ensures a sustained viral response
rate similar to that of standard treatment duration, with potential significant
reduction in cost and side effects." the authors report.
Researchers in Norway also conducted similar trials on 428 patients with HCV
genotype 2 or 3 to measure the success rate of 14 weeks of treatment with
peginterferon plus ribavirin.
Patients who achieved a viral response after 4 weeks were randomly assigned to
complete either 14 or 24 total weeks of treatment.
The study revealed that 81 percent of patients in the 14-week treatment group
achieved a constant viral response, with 86 percent still cured at 24-weeks
post-treatment.
About 91 percent of patients in the 24-week treatment group achieved a sustained
viral response, with 93 percent still cured at 24-weeks post-treatment.
"We cannot formally claim that 14 weeks treatment is non-inferior to 24 weeks
treatment," the authors conclude.
"However, the sustained viral response rate after 14 weeks treatment is high,
and although longer treatment may give a slightly better sustained viral
response rate, we believe considerable economical savings, good response to
re-treatment and less side effects make it rational to treat patients with
genotype 2 or 3 and rapid viral response for only 14 weeks," the authors said.
The findings appear in the January issue of Hepatology.
http://www.newkerala.com/one.php?action=fullnews&id=8991

Genetic Variation Doubles Risk of Liver Cancer

2008-03-26 03:28:28

Genetic Variation Doubles Risk of Liver Cancer
Testing could determine which cirrhosis patients should be screened for tumor
development
Posted 1/2/08
WEDNESDAY, Jan. 2 (HealthDay News) -- A single change in the epidermal growth
factor (EFG) gene may double the risk of developing liver tumors, especially
among people with cirrhosis, new research suggests.
Hepatocellular carcinoma is a liver tumor that is the third leading cause of
cancer death and may result from this genetic variation, said the researchers.
It is also the sixth most common solid tumor worldwide and often develops in
people who have cirrhosis.
Cirrhosis is a liver disease that can result from long-term alcohol abuse or
infection with the hepatitis C or B viruses. According to the U.S. National
Cancer Institute, about five percent of people with cirrhosis will develop liver
cancer.
The research, published in the Jan. 2 edition of the Journal of the American
Medical Association, suggested that people who have one or two guanine
nucleotides at the EFG gene site, instead of two adenine nucleotides, are at
significantly greater risk of cancer.
"If these results are confirmed, this EGF variation could be used to determine
which cirrhotic patients should be screened more intensively for tumor
development," lead author Dr. Kenneth Tanabe, chief of surgical oncology at the
Massachusetts General Hospital Cancer Center, said in a prepared statement. "In
addition, the molecular pathway controlled by EGF and its receptor, EGFR, which
is known to be important in several types of cancer, appears to be an excellent
target for chemoprevention studies. This is a deadly cancer, and so progress in
prevention and early detection is critically important."
The EFG gene normally works to increase tissue growth through the production of
EFG protein. Animal studies previously demonstrated a link between high levels
of EFG and tumor development. Blocking the protein's receptor has been shown to
prevent tumor growth. This is the first study to assess the relationship in
humans, according to the researchers.
When the EFG gene contains one or two guanine nucleotides (guanine instead of
the more common adenine), EFG is present in a greater quantity in the blood,
raising the carrier's risk of cancer, the study found.
Knowing this, the research team analyzed tissue samples from 207 Massachusetts
General Hospital patients with cirrhosis, the majority of whom were infected
with hepatitis C. Of that group, 59 had a hepatocellular carcinoma. The
researchers found that patients with at least one copy of the guanine nucleotide
were two times more likely than patients with only adenine nucleotides to
develop liver tumors. Patients with two guanine nucleotides were four times more
likely to develop liver tumors.
The researchers also found that EFG levels were highest in those people with two
guanine nucleotides.
The team then analyzed data from patients at the Paul Brousse Hospital in Paris,
most of whom suffered from alcoholic cirrhosis. These patients were three times
more likely to have a liver tumor if they had two guanine nucleotides than if
they had two adenine nucleotides.
The researchers noted that age and gender had no effect on the genetic risk of
developing the tumor. The majority of the subjects were Caucasian, but the
researchers found an increased risk of the genetic variation among Asian
patients. More than half of hepatocellular cancer cases worldwide occur in
China.
Tanabe and his colleagues called for a study of patients with cirrhosis before
the development of liver cancer to better understand other variables, such as
diet and medications, that could affect EFG levels.
More information
To learn more about liver cancer, visit the U.S. National Cancer Institute .
http://health.usnews.com/usnews/health/healthday/080102/genetic-variation-double\
s-risk-of-liver-cancer.htm

Hepatitis E: An emerging awareness of an old disease

2008-03-25 21:54:32

Hepatitis E: An emerging awareness of an old disease
R.H. Purcell, a, and S.U. Emersona
aLaboratory of Infectious Diseases, National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 50 South Drive MSC 8009, Bethesda, MD
20892-8009, USA
Associate Editor: M. Colombo. Available online 2 January 2008.
Although hepatitis E was recognized as a new disease in 1980, the virus was
first visualized in 1983 and its genome was cloned and characterized in 1991,
the disease is probably ancient but not recognized until modern times. Hepatitis
E is the most important or the second most important cause of acute clinical
hepatitis in adults throughout Asia, the Middle East and Africa. In contrast,
hepatitis E is rare in industrialized countries, but antibody (anti-HEV) is
found worldwide. HEV is a small round RNA-containing virus that is the only
member of the genus Hepevirus in the family Hepeviridae. Although similar to
hepatitis A virus in appearance, there are significant differences between the
two viruses. Hepatitis E is principally the result of a water-borne infection in
developing countries and is thought to be spread zoonotically (principally from
swine) in industrialized countries. Because diagnostic tests vary greatly in
specificity, sensitivity and availability, hepatitis E is probably
underdiagnosed. At present, control depends upon improved hygiene; a highly
efficacious vaccine has been developed and tested, but it is not presently
available.
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6W7C-4RGVVP1-3&_user=1\
0&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVers\
ion=0&_userid=10&md5=a011819cbe344cb37bdaead16ac9f5e2

FDA OKs 1st Quick MRSA Blood Test

2008-03-25 17:02:29

FDA OKs 1st Quick MRSA Blood Test
BD GeneOhm Test Delivers Results in 2 Hours, Says FDA
By Miranda Hitti
WebMD Medical News
Reviewed by Louise Chang, MD
Jan. 2, 2008 -- The FDA today announced that it has cleared for marketing the
first rapid blood test for MRSA (methicillin-resistant Staphylococcus aureus), a
drug-resistant staph bacterium that can cause deadly infections.
The new MRSA blood test -- called the BD GeneOhm StaphSR assay -- delivers
results in two hours. Other tests take several days.
"The BD GeneOhm test is good news for the public health community," the FDA's
Daniel Schultz, MD, says in a news release. The new test allows for "more
effective diagnosis and treatment," says Schultz, who directs the FDA's Center
for Devices and Radiological Health.
New MRSA Test
The new MRSA test uses molecular methods to identify whether a blood sample
contains genetic material from the MRSA bacterium or from more common, less
dangerous staph bacteria that can still be treated with the antibiotic
methicillin.
The FDA cleared the BD GeneOhm test based on the results of a clinical trial in
which the test identified 100% of MRSA-positive specimens and more than 98% of
more common, less dangerous staph specimens.
The FDA cautions that the new test should be used only in patients suspected of
a staph infection, not to monitor treatment of staph infections.
The test, which shouldn't be used as the sole basis for MRSA diagnosis, doesn't
rule out other complicating conditions or infections, the FDA also notes.
The BD GeneOhm StaphSR test is made by BD Diagnostics of Franklin Lakes, N.J.
http://www.webmd.com/news/20080102/fda-oks-1st-quick-mrsa-blood-test?ecd=wnl_nal\
_010208

HCV Advocate Web site

2008-03-25 09:05:59

Happy New Year from the staff of the HCV Advocate Web site! In case you missed
it, we have completely redesigned our newsletter and our 10th Anniversary Issue
can be viewed online in color! Here's the direct link to the English and
Spanish versions:
http://www.hcvadvocate.org/news/newsLetter/2008/advocate0108.html
In addition we have posted the following items to www.hcvadvocate.org and
www.hbvadvocate.org
*** Top 10 Downloads of 2007 - check out the documents that were most viewed
and downloaded by the HCV Advocate web audience.
*** HBV Journal Review, Vol 5, no 1, January 1, 2008, by Christine Kukka - read
the latest information about hepatitis B in our monthly journal.
*** Hepatitis C Treatments in Current Clinical Development - updated December
28, 2007 with the latest information on drugs in development to treat hepatitis
C.
***Updated Factsheets
. Extrahepatic Manifestations of HCV - we have updated many of our fact sheets
on the conditions that have been found to be associated with hepatitis C or are
seen more frequently in people infected with hepatitis C.
. HCV Education and Support - the following fact sheets have been recently
updated in our Education and Support section: A Brief History of HCV; Hepatitis
C: Disclosure; Dispelling Myths about HCV; Testing Positive for Antibodies to
the Hepatitis C Virus.
*** HCV ADVOCATE WEEKLY NEWS REVIEW: A Review of HCV, HBV and HIV/HCV
Coinfection Related News and Highlights, Week Ending: December 29th , 2007
To download pdf version click here
This Issue:
a.. Michigan voters likely will decide whether to legalize medical marijuana
in November
b.. State to hold itself liable in hep C bill
c.. 5 infected with hepatitis C after undergoing heart test at hospital
d.. For Chinese, a push against hepatitis stigma
e.. Stokes sentenced to 10.5 years in prison
f.. In Largest U.S. Hepatitis C Trial, Researchers Determine Weight-Based
Dosing Is Key to Optimal Treatment
g.. Researchers Show that Fibrosis can be Stopped, Cured and Reversed
h.. Hepatitis viruses detected in four more Green Cross blood products
i.. Eltrombopag Effective for Hepatitis C Patients With Low Blood-Platelet
Counts
Thanks!
Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate

Hemogenomics' NAT technology helps to reduce transmission of HIV, hepatitis in donor blood

2008-03-24 19:01:45

Hemogenomics' NAT technology helps to reduce transmission of HIV, hepatitis in
donor blood
Wednesday, January 02, 2008 08:00 IST
Nandita Vijay, Bangalore
Bangalore based Hemogenomics in association with Chiron, the diagnostic major,
part of Novartis, is now gearing up to increase the use of Nucleic Acid Testing
Technology (NAT) to screen human immunodeficiency virus - 1 (HIV-1), Hepatitis B
(HBV) and Hepatitis C (HCV) virus in donated blood.
The test is the first simultaneous and single tube NAT solution for HIV-1, HCV
and HBV. It detects the viral nucleic acid (RNA/DNA) and reduces the window
period of detection for all the three viruses from the current available
serological (ELISA) tests.
NAT combines the advantages of direct detection of the organism with sensitivity
several orders of magnitude higher than that of traditional methods. The
screening of blood for infectious markers (anti HIV 1 & 2, anti HCV and HBsAg)
is done using government approved test kits (Elisa or Rapid Kits). Despite these
efforts, residual risk of transfusion-transmitted infections remains because of
donors in the pre-sero conversion (window period), viral variants,
non-seroconverting (immunosilent) or delayed seroconverting carriers (atypical
seroconversion), stated Sumit Bagaria, President, Hemogenomics Pvt Ltd.
"The NAT technology along with serological testing can reduce the residual risk
to a great extent because it involves highly specific detection of an infectious
agent with much higher sensitivity," he added.
The company has been instrumental in bringing in state-of-the-art technologies
for disease prevention, diagnosis and monitoring.
"Opting for NAT at blood donation camps in South East Asia has been benefited
the population. In Singapore, among the 466,779 samples tested by NAT since
October 2007 labs, camps could identify 9 HCV and 10 HBV NAT yield samples (1 in
24,567). Similarly, in Thailand, Hong Kong and in Korea, the NAT yield rate is 1
in 11, 676 samples, 1 in 202,500 samples and 1 in 1, 46,628 samples
respectively. Despite these countries having a stringent donor counselling and
screening process, a high rate of regular repeat voluntary donation and use of
the most sensitive serological tests, have helped to identify a significant
number of samples which were NAT reactive but sero-negative.
In India, Indraprastha Apollo Hospitals, Delhi has taken the initiative for NAT
implementation for the first time in the country. In the first nine months of
implementing NAT, they were able to pick five (3 HBV and 2 HCV) NAT yield
samples among 13,331 samples tested (1 in 2,666). In Bangalore, Rotary TTK Blood
Bank has set up a dedicated centre to offer NAT.
The application of NAT screening for HIV and HCV is already prevalent. Many
countries have also added HBV NAT and others are planning to add it. USA also
added West Nile Virus (WNV) NAT to its blood safety programme.
Some of the countries already utilizing the benefits of NAT are the Asia Pacific
Region of Australia, India, Indonesia, Hong Kong, Korea, Malaysia, New Zealand,
Singapore, Thailand and Japan, Europe, Middle East and Africa which covers
Belgium, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Lithuania,
Poland, Portugal, Slovenia, Slovakia, South Africa, Egypt, Spain, Switzerland,
UK and Scotland. In the Americas, the countries include US, Brazil, Caribbean
and Canada.
http://www.pharmabiz.com/article/detnews.asp?articleid=42244

New Trial expected for jail rape case

2008-03-24 13:54:54

New Trial expected for jail rape case
HIV-fearing judge steps down
By Tracy McLaughlin
BARRIE -- A sex assault case returns to court today after the first trial was
derailed over the judge's insistence that the HIV-positive complainant testify
with a mask over his face or leave the courtroom.
A new trial date is expected to be set for Lee Wilde, charged with the sex
assault of another man in March 2007 while they were jail inmates at the Central
North Correctional Centre, known as the "superjail," in Penetanguishene.
During a two-day trial held last month, the male complainant, whose name is
banned from publication, testified that he is HIV positive and also has
hepatitis C. He admitted he did not reveal his HIV status to Wilde, who he
claims raped him three times in the prison cell.
BECAME ALARMED
But in midstream trial, on learning of his HIV status, trial judge Justice Jon
Jo Douglas became alarmed and ordered the complainant be masked and/or testify
electronically from another courtroom.
"Either you mask your witness, and/or move us to another courtroom or we do not
proceed," Douglas said.
Immediately following a break his court staff came out in blue rubber gloves and
enclosed paper exhibits the witness had touched in sealed plastic bags.
In a locking of horns, Crown attorney Karen McCleave refused to allow her key
witness, who is no longer an inmate, to be treated with disdain and applied for
a mistrial. The judge refused and ordered the trial proceed with the witness
masked.
EXPERT IN THE FIELD
The Crown then provided an affidavit from Dr. Giulio DiDiodato, an expert in the
field of infectious disease, who stated that neither HIV nor hepatitis C posed a
risk of infection unless there is direct exposure to the infected blood, vaginal
fluid or semen.
Douglas rejected the evidence.
The Crown again applied for several more mistrials and the judge refused. The
Crown then applied to a higher court. But the higher court dismissed the Crown's
application, noting it is the trial judge's jurisdictional right to conduct
safety precautions in the courtroom "even if his decision could be said to be
wrong," wrote Superior court Justice Margaret Eberhard.
In the end, Douglas voluntarily removed himself in the interests of the
integrity of the trial.
http://torontosun.com/News/Canada/2008/01/02/4748579-sun.html

Researchers at University of Sherbrooke publish new data on clinical trial research

2008-03-24 11:29:29

HEPATITIS ALERT
December 31, 2007
Researchers at University of Sherbrooke publish new data on clinical trial
research
According to a study from Longueuil, Canada, "Young injectors are a group
with high-risk behaviours, particularly with respect to HIV infection and
hepatitis C. A leading strategy to prevent these infections could be the
prevention of injection, especially among the youngest individuals. We report
analyses on initiation into drug injection from a prospective cohort study of
street youth conducted in Montreal, Canada."
"Among 118 non-injector participants under 18 years of age followed for an
average of 1.31 years, we estimated an incidence rate of injection of 22.7 per
100 person-years. Independent predictors of initiation were: a lifetime history
of use of <= 4 types of drugs, recent daily alcohol drinking, a recent episode
of homelessness, a lifetime history of rape, and recent involvement in survival
sex. The observed high rate of initiation into injection clearly indicates that
interventions to prevent injection should target especially adolescent street
youth," wrote E. Roy and colleagues, University of Sherbrooke.
The researchers concluded: "These interventions should address
simultaneously individual and structural factors, such as substance abuse and
living conditions."
Roy and colleagues published the results of their research in Drugs -
Education Prevention and Policy (Risk factors for initiation into drug injection
among adolescent street youth. Drugs - Education Prevention and Policy,
2007;14(5):389-399).
For additional information, contact E. Roy, University of Sherbrooke,
Faculty Med & Science Sante, Programme Etud & rech Toxicomanie, Campus
Longueuil, 1111 Rue St. Charles Ouest, Tour O, Longueuil, PQ J4K 5G4, Canada.
www.NewsRx.com

LifeCycle Pharma to start Phase II trials of hepatitis drug

2008-03-24 10:23:44

LifeCycle Pharma to start Phase II trials of hepatitis drug
COPENHAGEN (Thomson Financial) - LifeCycle Pharma said it has initiated Phase II
clinical trials of LCP-Tacro for the treatment of autoimmune hepatitis (AIH),
also referred to as chronic active hepatitis, a disease which causes a person's
body to reject its own liver.
The clinical trial is expected to enroll up to 60 patients in up to 12 centres
throughout the US and Canada and the first results are expected to be reported
in the first half of 2009.
The company wants LCP-Tacro to be the first FDA-approved drug indicated for the
treatment of AIH.
Hans.Chumakonde@...
http://www.forbes.com/markets/feeds/afx/2008/01/02/afx4485947.html

Changes to my info posts.........

2008-03-24 00:33:46

Hello and Happy New Year! I am updating my *info post* list this year. I
will no longer be posting to groups other than the ones I own unless contacted
again by the owner of the group stating that you want your group to remain on
the list. If you want to be left on the HCV information list please email me
and give me the name of your group. I will make the changes around January
10th. I also wanted to remind the groups owners (some of whom have made
monetary promises over the past 5 years and have never contributed a penny) that
all these posts are made possible through H.E.A.L.S of the South and donations
throughout the year would be appreciated. They do not even need to be large
donations........ every dollar helps and even one dollar in an envelope is
appreciated. There are PayPal buttons at www.HEALSoftheSouth.com and
www.HEALSoftheSouth.org that can be utilized or you can mail a tax deductible
contribution to:
H.E.A.L.S of the South
PO Box 180813
Tallahassee, FL 32318
Without donations, I will no longer have an internet connection and therefore
the information posts will disappear. If I am able to remain on a dial up

Six former Stokes patients have hepatitis C

2008-03-23 22:43:18

Six former Stokes patients have hepatitis C
Tuesday, January 01, 2008
By Ken Kolker
The Grand Rapids Press
GRAND RAPIDS -- The results of blood tests are trickling in for former patients
of Dr. Robert Stokes, the disgraced dermatologist whose medical practices
allegedly posed a risk for the spread of communicable diseases.
So far, six former patients have tested positive for hepatitis C, state health
officials said. The officials say in terms of percentages, the overall results
have been encouraging, though it still is too early to draw conclusions.
Officials have received test results for 710 of the doctor's 13,000 or so
patients in Kent and Montcalm counties. Many have yet to be tested.
The six who tested positive for hepatitis C represent fewer than 1 percent of
those tested. Hepatitis C is a blood-borne disease that can lead to liver
failure and death, state health officials said.
The figure is below the rate of 1.6 percent in the typical population, according
to the U.S. C